| pubmed-article:10585342 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10585342 | lifeskim:mentions | umls-concept:C0013080 | lld:lifeskim |
| pubmed-article:10585342 | lifeskim:mentions | umls-concept:C1141639 | lld:lifeskim |
| pubmed-article:10585342 | lifeskim:mentions | umls-concept:C0220908 | lld:lifeskim |
| pubmed-article:10585342 | lifeskim:mentions | umls-concept:C1545380 | lld:lifeskim |
| pubmed-article:10585342 | lifeskim:mentions | umls-concept:C0020980 | lld:lifeskim |
| pubmed-article:10585342 | lifeskim:mentions | umls-concept:C1527178 | lld:lifeskim |
| pubmed-article:10585342 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:10585342 | pubmed:dateCreated | 1999-12-17 | lld:pubmed |
| pubmed-article:10585342 | pubmed:abstractText | Serum human chorionic gonadotropin (hCG) and hCG free beta-subunit tests are used in combination with unconjugated estriol and alpha-fetoprotein in the triple screen test, and with the addition of inhibin-A in the quadruple marker test for detecting Down syndrome in the second trimester of pregnancy. These tests have a limited detection rate for Down syndrome: approximately 40% for hCG or free beta-subunit alone, approximately 60% for the triple screen test, and approximately 70% for the quadruple marker test, all at 5%, or a relatively high, false-positive rate. New tests are needed with higher detection and lower false rates. Hyperglycosylated hCG (also known as invasive trophoblast antigen or ITA) is a new test. It specifically detects a unique oligosaccharide variant of hCG associated with Down syndrome pregnancies. We evaluated this new Down syndrome-directed test in prenatal diagnosis. | lld:pubmed |
| pubmed-article:10585342 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10585342 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10585342 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10585342 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10585342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10585342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10585342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10585342 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10585342 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:10585342 | pubmed:issn | 0009-9147 | lld:pubmed |
| pubmed-article:10585342 | pubmed:author | pubmed-author:MahoneyM JMJ | lld:pubmed |
| pubmed-article:10585342 | pubmed:author | pubmed-author:ColeL ALA | lld:pubmed |
| pubmed-article:10585342 | pubmed:author | pubmed-author:Bahado-SinghR... | lld:pubmed |
| pubmed-article:10585342 | pubmed:author | pubmed-author:ShahabiSS | lld:pubmed |
| pubmed-article:10585342 | pubmed:author | pubmed-author:OzU AUA | lld:pubmed |
| pubmed-article:10585342 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10585342 | pubmed:volume | 45 | lld:pubmed |
| pubmed-article:10585342 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10585342 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10585342 | pubmed:pagination | 2109-19 | lld:pubmed |
| pubmed-article:10585342 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:10585342 | pubmed:meshHeading | pubmed-meshheading:10585342... | lld:pubmed |
| pubmed-article:10585342 | pubmed:meshHeading | pubmed-meshheading:10585342... | lld:pubmed |
| pubmed-article:10585342 | pubmed:meshHeading | pubmed-meshheading:10585342... | lld:pubmed |
| pubmed-article:10585342 | pubmed:meshHeading | pubmed-meshheading:10585342... | lld:pubmed |
| pubmed-article:10585342 | pubmed:meshHeading | pubmed-meshheading:10585342... | lld:pubmed |
| pubmed-article:10585342 | pubmed:meshHeading | pubmed-meshheading:10585342... | lld:pubmed |
| pubmed-article:10585342 | pubmed:meshHeading | pubmed-meshheading:10585342... | lld:pubmed |
| pubmed-article:10585342 | pubmed:meshHeading | pubmed-meshheading:10585342... | lld:pubmed |
| pubmed-article:10585342 | pubmed:meshHeading | pubmed-meshheading:10585342... | lld:pubmed |
| pubmed-article:10585342 | pubmed:meshHeading | pubmed-meshheading:10585342... | lld:pubmed |
| pubmed-article:10585342 | pubmed:meshHeading | pubmed-meshheading:10585342... | lld:pubmed |
| pubmed-article:10585342 | pubmed:meshHeading | pubmed-meshheading:10585342... | lld:pubmed |
| pubmed-article:10585342 | pubmed:meshHeading | pubmed-meshheading:10585342... | lld:pubmed |
| pubmed-article:10585342 | pubmed:meshHeading | pubmed-meshheading:10585342... | lld:pubmed |
| pubmed-article:10585342 | pubmed:meshHeading | pubmed-meshheading:10585342... | lld:pubmed |
| pubmed-article:10585342 | pubmed:meshHeading | pubmed-meshheading:10585342... | lld:pubmed |
| pubmed-article:10585342 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10585342 | pubmed:articleTitle | Hyperglycosylated human chorionic gonadotropin (invasive trophoblast antigen) immunoassay: A new basis for gestational Down syndrome screening. | lld:pubmed |
| pubmed-article:10585342 | pubmed:affiliation | Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT 06510, USA. larry@hCGlab.com | lld:pubmed |
| pubmed-article:10585342 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10585342 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10585342 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10585342 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10585342 | lld:pubmed |
